Transgene

Equities

TNG

FR0005175080

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:35:17 2024-05-17 am EDT			5-day change	1st Jan Change
1.326 ^EUR	-0.15%		-1.63%	-3.21%

Apr. 10	Transgene: presents vaccine results at AACR	CF
Mar. 28	Transgene CFO Steps Down; Successor Assumes Office	MT

Transgene SA Announces Revenue Results for the Quarter Ended March 31, 2017; Provides Cash Burn Guidance for 2017

April 25, 2017 at 12:00 pm EDT

Transgene SA announced revenue results for the quarter ended March 31, 2017. For the quarter, operating revenue was EUR 1.9 million against EUR 2.0 million a year ago.

Transgene confirms that it expects 2017 cash burn to be around EUR 30 million, which includes the development plan as currently programmed, as well as a $4 million milestone payment to SillaJen Inc. This payment will be made in the second quarter of 2017 following the inclusion of the first patient in Europe in the Phase 3 trial evaluating Pexa-Vec in patients with advanced liver cancer.

Latest news about Transgene

Transgene: presents vaccine results at AACR	Apr. 10	CF
Transgene CFO Steps Down; Successor Assumes Office	Mar. 28	MT
Transcript : Transgene SA, 2023 Earnings Call, Mar 27, 2024	Mar. 27
Transgene SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Transgene SA Announces Chief Financial Officer Changes	Mar. 27	CI
Transgene SA Promotes Christelle Schwoerer to Chief Human Resources Officer, Effective from April 1, 2024, and She Also Joins the Executive Committee	Mar. 27	CI
Fractyl Health Reports 'Promising' Preclinical Findings From Rejuva Platform; Shares Fall	Mar. 12	MT
Transgene, NEC Corporation and BostonGene Corporation Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050	Mar. 05	CI
Transgene Appoints Chief Business Officer	Jan. 23	MT
Transgene Appoints James Wentworth as Chief Business Officer and Member of Executive Management Team	Jan. 22	CI
Transgene: new CFO, share price rises	Dec. 06	CF
Biotech Group Transgene Names CFO	Dec. 06	MT
UniQure Says US FDA Clears Investigational New Drug Application for Fabry Disease Candidate	Nov. 29	MT
Transgene and BioInvent International AB Announces First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA	23-10-10	CI
Transcript : Transgene SA, H1 2023 Earnings Call, Sep 20, 2023	23-09-20
Transgene SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-20	CI
Transgene Obtains $15 Million from Sale of Minority Stake in Chinese Biopharmaceutical Group	23-07-18	MT
Transgene: proceeds from sale received	23-07-18	CF
4D Molecular Reports Positive Interim Data in Phase 1/2 AEROW Clinical Trial of 4D-710; Shares Jump	23-06-07	MT
TRANSGENE : Invest Securities confirms its Buy rating	23-06-06	CF
Transgene: presents new data at ASCO 2023	23-06-06	CF
Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023	23-06-06	CI
BioInvent Ready for Combination Studies with BT-001	23-06-05	CI
TRANSGENE : Invest Securities reiterates its recommendation	23-06-05	CF
Transgene: boosted by data on its cancer vaccine	23-06-05	CF

Chart Transgene

Duration

Period

More charts

Company Profile

Transgene, part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. Transgene has a portfolio of 5 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene is based in Strasbourg, France, and has additional operations in Lyon and China.

Sector

Biotechnology & Medical Research

Calendar

2024-06-05 - Oddo BHF Nextcap Forum

More about the company

Income Statement Evolution

More financial data

Ratings for Transgene

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.328 EUR

Average target price

3.5 EUR

Spread / Average Target

+163.55%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
TRANSGENE	-3.21%	145M
VERTEX PHARMACEUTICALS INCORPORATED	+8.89%	114B
REGENERON PHARMACEUTICALS, INC.	+11.46%	104B
BIONTECH SE	-12.60%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-3.18%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+8.00%	14.28B
SAREPTA THERAPEUTICS, INC.	+34.55%	12.55B

Bio Therapeutic Drugs